AstraZeneca’s Tagrisso secures FDA breakthrough therapy designation for first-line treatment of NSCLC
AstraZeneca has achieved a significant milestone with its lung cancer drug, Tagrisso (osimertinib), which has recently been granted the Breakthrough Therapy Designation (BTD) by the ... Read More
AstraZeneca’s Lynparza shows promising results in phase 3 ovarian cancer trial
AstraZeneca has reported significant findings from its phase 3 trial, SOLO-2, for its ovarian cancer drug Lynparza (olaparib), demonstrating considerable improvement in survival chances for ... Read More
AstraZeneca and Sanofi Pasteur forge €615m alliance to develop infant respiratory drug MEDI8897
AstraZeneca’s biotech arm, MedImmune, and Sanofi Pasteur, the vaccines division of French pharmaceutical giant Sanofi, have entered into a significant research and development collaboration. The ... Read More